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Interferon alfa (IFN-a) is the primary treatment for
chronic hepatitis B. The standard duration of IFN-a therapy
is considered 16 weeks; however, the optimal treatment
length is still poorly defined. We evaluated the efficacy and
acceptability of prolonged IFN-a treatment in patients with
chronic hepatitis B. To investigate whether treatment prolon-
gation could enhance the rate of hepatitis B e antigen
(HBeAg) seroconversion, we conducted a prospective, con-
trolled, multicenter trial in which all patients were treated
with a standard regimen of 10 million units IFN-a 3 times
per week over 16 weeks. Patients who were still HBeAg-
positive after 16 weeks of therapy were randomized to
prolongation of the identical regimen up to 32 weeks
(prolonged therapy) or discontinuation of treatment (stan-
dard therapy). Among the 162 patients who entered the
study, 27 (17%) were HBeAg-negative after the first 16
weeks of treatment, and 118 were randomized to standard
or prolonged therapy. After randomization, a response
(HBeAg seroconversion and sustained hepatitis B virus
[HBV]-DNA negativity) was observed in 7 of the 57 (12%)
patients assigned to standard therapy versus 17 of the 61
(28%) patients assigned to prolonged therapy (P 5 .04). A
low level of viral replication after 16 weeks of treatment, as
indicated by serum HBV-DNA values under 10 pg/mL, was
found to be the only independent predictor of response
(52% vs. 0%; P F .001) during prolonged therapy. The
prolonged IFN-a schedule was well tolerated in the large
majority of patients. In chronic hepatitis B, prolongation of
IFN-a therapy up to 32 weeks is superior to a standard
course of 16 weeks. Those patients who exhibit a low level
of viral replication at the end of the standard regimen
benefit most from prolonged treatment. (HEPATOLOGY 1999;
30:238-243.)
Worldwide, chronic hepatitis B virus (HBV) infection is a
major cause of cirrhosis and hepatocellular carcinoma. Clear-
ance of hepatitis B e antigen (HBeAg) indicates transition to a
state of low-level viral replication that is accompanied by
biochemical remission of liver disease and prolonged sur-
vival.1-3 Interferon alfa (IFN-a) has emerged as one of the
most effective treatments for chronic hepatitis B, inducing
HBeAg seroconversion in about one third of the patients.4,5
Many attempts to enhance this response rate have been
unsuccessful. Treatment with nucleoside analogues, such as
lamivudine, or combination of these agents with IFN-a, does
not yet appear to significantly increase the HBeAg seroconver-
sion rate,6-8 whereas the use of priming therapy with predni-
sone has not been generally accepted as a result of a lack of
consistent results and the risk of hepatic decompensation.4,9
How long we should treat chronic HBV patients with IFN-a is
still not established. The standard duration of treatment is
considered 16 weeks. In several studies, IFN-a was given for
a longer period, and some suggest additional benefit of
prolonged therapy.10,11 However, these studies contain a small
number of patients, show considerable heterogeneity in
patient population and response rates, and the results should
therefore be interpreted with caution. In an uncontrolled
pilot study, we successfully prolonged IFN-a treatment in
those patients who approximated HBeAg seroconversion, as
demonstrated by a continuous decrease of quantified serum
HBV-DNA and HBeAg values, at the end of standard IFN-a
therapy.12 Therefore, we initiated a large, prospective, random-
ized, controlled trial investigating the efficacy of treatment
prolongation with an additional 16 weeks in those patients
who did not respond with HBeAg seroconversion during a
standard 16-week IFN-a course.
PATIENTS AND METHODS
Patients. One hundred sixty-two patients from 16 European
hepatologic centers (EUROHEP)13 were enrolled after central evalu-
ation of their eligibility. The inclusion criteria were age between 18
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and 70 years; hepatitis B surface antigen (HBsAg) positivity in serum
for at least 6 months; presence of HBeAg and HBV DNA (by
hybridization methodology) in serum, and elevation of either serum
aspartate transaminase (AST) or alanine transaminase (ALT) values,
as documented on 3 occasions in the 3 months before entry; and
histological evidence of chronic hepatitis on a liver biopsy taken in
the 6 months preceding enrollment. Patients were excluded for the
following reasons: presence of serum antibodies against hepatitis
delta, hepatitis C, or human immunodeficiency virus; recent alcohol
abuse or drug addiction; previous IFN-a course with a minimum
duration of 12 weeks using at least 30 million units (MU) per week;
any antiviral or immune modulatory therapy in the preceding
6 months; immunocompromised patients; pregnancy; females
of fertile age with inadequate contraception; significant medical
illness potentially interfering with completion of the study; in-
adequate levels of hemoglobin (,6 mmol/L), platelets (,70 3
109/L), or leukocytes (3 3 109/L); decompensated liver disease with
a bilirubin . 34 µmol/L, albumin , 32 g/L, or history of either
ascites, bleeding esophageal varices, and hepatic encephalopathy.
During the screening period, 1 patient died in a car accident, and 7
others were excluded from the start of treatment after initial
approval of their eligibility: 4 decided not to participate in the study,
2 lost serum HBeAg, and 1 became pregnant. The study was formally
approved by the ethical committee of each participating center, and
the patients were required to give written informed consent before
entering the study.
Design of the Study. Recombinant IFN-a (alfa-2b, Intron-A; Scher-
ing-Plough, Kenilworth, NJ) was administered subcutaneously to all
patients at a dose of 10 MU three times per week during a 16-week
period (phase A). Patients who were HBeAg-seropositive after 16
weeks of treatment were randomly assigned to either prolongation
of the same IFN-a regimen up to 32 weeks (prolonged therapy) or
discontinuation of IFN-a after 16 weeks (standard therapy) (phase
B). Those not randomized were followed without further therapy
(Fig. 1). Patients were instructed to self-administer IFN-a to make
further treatment on an outpatient basis feasible. All patients were
seen at the outpatient clinic for routine examination and laboratory
assessment at weeks 28, 24, 0, 2, and 4 of therapy, and monthly in
the period thereafter up to 32 weeks; after 32 weeks, patients were
seen every 4 to 8 weeks until 52 weeks after the start of therapy. On
all occasions, hematological studies (hemoglobin, leukocytes, plate-
lets), and serum markers of viral replication (HBeAg and HBV DNA)
and hepatic inflammation (AST) were assessed; every 2 months,
additional laboratory investigations including measurements of
serum bilirubin, albumin, ALT, prothrombin time, HBsAg, and
antibodies against HBeAg and HBsAg were performed. To score
acceptability and safety of prolonged IFN-a treatment, a standard-
ized questionnaire, in which patients could notify the intensity of
side-effects in 3 scores (0 5 none, 1 5 mild, 2 5 moderate), was
completed every 2 months. Predefined clinical and laboratory
toxicity criteria were used for dose reduction and discontinuation of
IFN-a.
Laboratory Evaluation. Routine biochemical and hematologic tests
were performed at the participating centers using automated tech-
niques. To correct for heterogeneity of local assays and to ensure
standardized results, levels of AST and ALT were expressed as values
representing a ratio to the local upper limit of normal. All HBV
markers were assessed centrally at the Department of Virology,
Erasmus University in Rotterdam. HBeAg, antibodies against HBeAg,
HBsAg, and antibodies against HBsAg were measured using routine
commercially available enzyme immunoassays (Abbott Laborato-
ries, North Chicago, IL). HBV DNA was determined by a solution
hybridization assay that uses a 125I-labeled probe (cut-off: 1.7 pg/mL;
Genostics, Abbott Laboratories). The criteria for response to therapy
were defined as loss of HBeAg and HBV DNA that sustained until the
end of follow-up at week 52. All other patients were considered
nonresponders.
All patients underwent a liver biopsy in the 6 months before
treatment; a second liver biopsy was proposed to each patient at 1
year after the start of therapy. Biopsy specimens were evaluated by a
single experienced pathologist who was blinded with respect to the
treatment regimen and chronological order of the biopsies. Histologi-
cal scoring was performed according to the Desmet modification of
the histological activity index as described by Knodell et al.14,15
Randomization and Statistical Analysis. To enable optimal intention-
to-treat analysis, we chose to randomize as late as possible within
the initial 16-week course of treatment (phase A). The randomiza-
tion was performed centrally after 14 weeks of treatment only for
those patients being HBeAg-positive after the first 12 weeks of
treatment. Criteria other than HBeAg negativity that precluded
randomization were discontinuation of IFN-a during the first 12
weeks, unwillingness of the patient to continue treatment beyond 16
weeks, and incompleteness of collected data. To balance the
pretreatment response probability, the randomized groups were
stratified according to serum HBV-DNA level (more or less than 150
pg/mL) and AST level (more or less than twice the upper limit of
normal) at entry. Within each stratum, patients were randomly
assigned to standard or prolonged IFN-a therapy using consecu-
tively numbered, sealed, opaque envelopes. The result of the
randomization procedure was sent by fax to the participating centers
on the same day. It was pre-established that patients who became
HBeAg-negative between weeks 12 and 16, and thus in retrospec-
tion, not eligible for phase B, were withdrawn from the randomized
study and followed without further therapy until 52 weeks after the
start of treatment. To achieve a comparable observation time after
cessation of therapy, we separately analyzed the results for the
responders of the prolonged treatment group after extension of the
follow-up period with 16 weeks.
To obtain a power (1-b) of greater than 80% (a 5 .05), an
estimated number of 120 patients should be eligible for randomiza-
tion after 16 weeks, assuming an HBeAg seroconversion rate of 5%
for standard treatment (no further therapy after randomization) and
25% for prolonged treatment (another 16 weeks of IFN-a after
randomization), and a 5% drop-out after randomization. Intention-
to-treat analysis was performed for randomized patients who were
HBeAg-positive at week 16. The Wilcoxon rank sum and signed
rank tests were used to compare unpaired and paired observations,
respectively. Comparison of discrete variables was accomplished
using the x2 test or Fisher’s exact test. Rate of response to therapy
was calculated with life-table analysis. Actuarial curves of response
were compared by log rank testing, and independent prediction of
response was evaluated by stepwise logistic regression analysis.
Before multivariate analysis, logarithmic transformation was applied
for HBV DNA and AST because of skewed distribution.
RESULTS
Twenty-seven of the 162 (17%) patients who started IFN-a
therapy exhibited clearance of HBeAg and HBV DNA duringFIG. 1. Design of the study.
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phase A (Fig. 2). Nine of these 27 patients were randomized
(standard therapy n 5 7; prolonged therapy n 5 2) but
appeared to be HBeAg-negative at week 16, and were thus
excluded from further analysis of phase B. Seventeen other
patients were not eligible for randomization, because they
either discontinued treatment in phase A (n 5 12), refused to
continue therapy in phase B (n 5 4), or were in retrospect
HBV-DNA–negative at the start of therapy (n 5 1). Of the 118
patients analyzed after randomization (phase B), 4 (7%)
assigned to standard therapy and 1 (2%) to prolonged therapy
did not complete the entire follow-up period of 1 year. These
5 patients were considered nonresponders, because all final
samples obtained showed HBeAg positivity.
Patient characteristics of the 162 patients who started
treatment (phase A) and the 118 patients who were analyzed
after randomization (phase B; standard therapy n 5 57,
prolonged therapy n 5 61) are shown in Table 1. The 2
randomized groups were similar with respect to age, sex,
race, sexual preference, history of acute hepatitis, known
duration of hepatitis, presence of cirrhosis, and levels of HBV
DNA and transaminases, both at entry and at the time of
randomization. After randomization, a response (sustained
HBeAg and HBV-DNA negativity) was observed in 7 of the 57
(12%) patients of the standard-treatment group and in 17 of
the 61 (28%) patients of the prolonged treatment group (P 5
.04) (Fig. 2). The median time interval between randomiza-
tion and response was 16 weeks for both the standard and
prolonged-treatment group. In the prolonged-treatment group,
56% of the patients who responded lost HBeAg while still
receiving IFN-a. Twenty-three of the 24 responders (96%)
developed antibodies against HBeAg. Two patients in the
standard-treatment group and 1 in the prolonged-treatment
group demonstrated clearance of HBeAg with subsequent
HBeAg reappearance during posttreatment follow-up. The
HBeAg response in the prolonged-treatment group remained
unchanged after an extended follow-up of 16 weeks, because
HBeAg reactivation did not occur during this period. Of the
27 patients who became HBeAg-negative during phase A, 6
exhibited an HBeAg reactivation, leaving 21 responders at 52
weeks. Combining the response rate of phase A (13%) with
the response rate of phase B (12% for standard therapy and
28% for prolonged therapy), the cumulative response probabil-
ity obtained for standard and prolonged therapy equals 24%
and 37%, respectively. Among the patients who were HBV-
DNA–positive at randomization (Table 1), sustained negativ-
ity of HBV DNA with persistent HBeAg positivity was
observed in 4 of the 45 (9%) of the standard-treatment group
and in 8 of the 44 (18%) of the prolonged-treatment group
FIG. 2. Kaplan-Meier estimate of HBeAg disappearance during the initial
16 weeks of IFN-a therapy (phase A) among all patients who started
treatment (n 5 162; left), and of sustained HBeAg disappearance (response)
for patients being HBeAg-positive at week 16 and randomized to standard
(no further therapy after randomization) or prolonged treatment (another 16
weeks of IFN-a after randomization) (phase B; n 5 118; right).
TABLE 1. Characteristics of All Patients and of the Patients Randomized to Standard and Prolonged IFN-a Treatment at Entry
and After Randomization at the Start of Phase B
Total Group (n 5 162)
Randomized Group (n 5 118)
Standard (n 5 57) Prolonged (n 5 61)
At entry
Age (yr)*† 34 (16-70) 31 (17-70) 33 (16-64)
Male (%) 121 (75) 45 (79) 40 (66)
Race
White (%) 130 (80) 47 (82) 48 (79)
Asian (%) 23 (14) 5 (9) 11 (18)
Other (%) 9 (6) 5 (9) 2 (3)
Duration HBsAg positivity (yr)* 2.1 (0.5-20) 2.0 (0.5-20) 2.0 (0.5-20)
History acute hepatitis (%) 18 (11) 4 (7) 8 (13)
Cirrhosis (%) 27 (17) 6 (11) 9 (15)
HBV DNA in serum (pg/mL)* 115 (2-1065) 144 (2-883) 117 (2-1065)
AST in serum*‡ 1.64 (0.61-10.53) 1.40 (0.61-6.13) 1.61 (0.67-10.53)
ALT in serum*‡ 3.31 (0.72-20.09) 2.96 (0.72-15.00) 3.06 (0.94-20.09)
After randomization (week 16)
HBeAg positivity (%) — 57 (100) 61 (100)
HBV-DNA positivity (%) — 45 (79) 44 (72)
HBV-DNA in serum (pg/mL)* — 37 (2-503) 30 (2-826)
AST in serum*‡ — 1.17 (0.40-16.76) 1.18 (0.50-11.11)
*Median (range).
†Five patients (3 in the prolonged-therapy group and 2 in the standard-therapy group) were younger than 18 years old. This protocol violation was
considered minor, and these patients were thus retained in the study.
‡Elevation of AST or ALT/upper limit of normal range.
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(P 5 .11). None of the patients allocated to standard
treatment lost HBsAg, whereas 3 (5%) patients in the
prolonged group did so. At the last observation, 76% of the
responders and 33% of the nonresponders had normal AST
levels (P , .001). Irrespective of response, 10 of the 32
patients (31%) with elevated AST levels at randomization in
the standard-therapy group versus 16 of the 39 patients
(41%) in the prolonged-therapy group exhibited persistent
normalization of AST (P 5 .27).
Histological scoring of pretreatment biopsies was per-
formed for 147 of the 162 (91%) patients who entered the
study and for 108 of the 118 (92%) randomized patients.
Twelve initial biopsy specimens had not been received by the
consulting pathologist, and 3 were considered inadequate for
histological grading and staging. No significant difference in
histological activity index score was found between the
randomized groups in initial biopsy specimens (standard
therapy n 5 53; mean score: 4.9 6 0.5 vs. prolonged therapy
n 5 55; mean score: 5.6 6 0.4; P 5 .13). Paired liver biopsies
were available for 50 (42%) of the 118 randomized patients. A
marked histological improvement after IFN-a therapy was
observed among responders of both the standard- and pro-
longed-therapy groups, primarily as a result of regression of
portal, periportal, and lobular inflammation (Table 2). There
was no change in degree of fibrosis and confluent necrosis.
Because there appeared to be an association between the
probability of response and the likelihood of undergoing a
posttreatment biopsy (79% among responders vs. 37% among
nonresponders), correlation of histological changes with
scheme of therapy was not considered feasible.
To assess which patients may benefit from prolonged
IFN-a treatment, a response prediction analysis was per-
formed for the patients assigned to prolonged therapy (Table
3). In the univariate analysis, patients with higher age,
presence of cirrhosis, and high AST values showed a better
response rate during prolonged therapy. These differences,
however, did not reach statistical significance. Low HBV-DNA
level at randomization was strongly associated with response
during prolonged therapy (P , .001), while low HBV DNA at
entry tended toward significance (P 5 .07). By multivariate
analysis, only HBV-DNA level at randomization was shown to
be predictive of response (P , .001). In fact, all patients
responding in the prolonged-treatment regimen had HBV-
DNA levels below 10 pg/mL at randomization (Fig 3).
A transient flu-like syndrome with fever and myalgia was
seen in nearly all of the patients during the initial days of
IFN-a treatment. Other frequent side-effects, encountered in
at least 20% of the patients, were fatigue, asthenia, anorexia,
arthralgia, and various neuropsychiatric symptoms including
depression and irritability. During the initial 16 weeks of
therapy (phase A), dose modification as a result of adverse
effects was required in 16 of the 162 patients (10%). Eleven of
these 16 patients stopped treatment before randomization.
The reasons for discontinuation were flu-like symptoms in 3
patients, psychosis or depression in 3, dizziness in 2, fatigue
in 1, thrombocytopenia in 1, and exacerbation of the HBV
TABLE 2. Mean Histological Scoring 6 SEM of Paired Liver Biopsies Obtained From Patients Randomized to Standard and Prolonged IFN-a Treatment
n
Grading Score Fibrosis Score HAI Score
Entry Follow-up Entry Follow-up Entry Follow-up
Standard therapy
Nonresponse 15 3.3 6 0.7 2.9 6 0.6 1.5 6 1.0 1.8 6 0.2 4.8 6 0.9 4.7 6 0.6
Response 4 3.3 6 2.4 1.3 6 0.5 2.0 6 0.9 1.8 6 0.8 5.3 6 3.2 3.0 6 2.2
Prolonged therapy
Nonresponse 18 3.4 6 0.5 2.6 6 0.3 1.7 6 0.9 1.8 6 0.3 5.0 6 0.7 4.3 6 0.5
Response 13 4.5 6 0.9 1.6 6 0.3 2.2 6 0.4 2.2 6 0.3 6.6 6 1.0 3.8 6 0.5
NOTE. Grading score: sum of periportal hepatitis, confluent necrosis, focal necrosis, and portal inflammation.
Abbreviation: HAI, histological activity index; sum of grading and fibrosis score.
TABLE 3. Characteristics of Patients Assigned to Prolonged IFN-a
Treatment (n 5 61) in Relation to HBeAg Response
n HBeAg Response P
Sex
Male 40 28% (9%) .93
Female 21 29% (25%)
Age
#35 years 34 21% (10%) .14
.35 years 27 37% (15%)
HBsAg positivity
#2 years 33 24% (15%) .56
.2 years 28 32% (10%)
History of acute hepatitis
No 53 30% (11%) .33
Yes 8 13% (25%)
Asian origin
No 50 30% (13%) .39
Yes 11 18% (0%)
Cirrhosis
No 52 25% (12%) .20
Yes 9 44% (17%)
AST at entry
#1.5 normal 24 20% (13%) .26
.1.5 normal 37 32% (12%)
AST at randomization
#1.5 normal 35 31% (16%) .56
.1.5 normal 26 23% (5%)
HBV DNA at entry
#100 pg/mL 29 38% (16%) .07
.100 pg/mL 32 19% (11%)
HBV DNA at randomization
#10 pg/mL 33 52% (21%)* ,.001
.10 pg/mL 28 0% (6%)
NOTE. The given P values were calculated from differences in HBeAg
response within this group of 61 patients. Percentages in parentheses denote
the response rate of patients with similar characteristics randomized to
standard IFN-a treatment (n 5 57).
*Among patients with HBV DNA #10 pg/mL at randomization, the HBeAg
response was significantly higher in the group of prolonged therapy as
compared with standard therapy (P 5 .02). In patients randomized to
standard therapy, 5 of the 24 (21%) with HBV DNA #10 pg/mL at
randomization versus 2 of the 33 (6%) with HBV DNA .10 pg/mL exhibited
a response (P 5 .002).
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infection with hepatic decompensation in 1. In 1 patient, trial
medication was interrupted because lung cancer was diag-
nosed after 12 weeks of therapy. After randomization (phase
B), dose reduction was necessary in 7 of the 61 patients (11%)
receiving prolonged IFN-a therapy because of depression,
fatigue, hair loss, and headache; 3 of the 7 patients discontin-
ued therapy prematurely, all as a result of a combination of
these side-effects. One patient fractured a rib after he col-
lapsed as a result of dizziness in week 32 just after the
scheduled treatment had been completed. None of the
patients died during the study. A standardized scoring system
to evaluate the tolerance of prolonged treatment only showed
aggravation of hair loss after 32 weeks as compared with 16
weeks of IFN-a therapy (Table 4). There was no significant
increase in severity of other side-effects, such as fatigue,
depressive feelings, anorexia, and concentration distur-
bances. Nearly all adverse effects attributed to IFN-a were
reversible with dose modification or cessation of therapy.
DISCUSSION
IFN-a is the only agent with an established long-term
beneficial effect on the natural history of chronic hepatitis B.1
The currently recommended IFN-a treatment schedule is
either 5 MU daily or 10 MU three times per week for 16
weeks.16 We demonstrated an increased clearance of both
HBeAg and HBV DNA after prolonged therapy as compared
with treatment with the standard duration of 16 weeks. The
enhanced efficacy of prolonged treatment was so pronounced
that in future treatment regimens comprising both IFN-a
monotherapy as its combination with other antiviral agents,
prolongation of IFN-a therapy up to 32 weeks should be
considered.
The beneficial effect of treatment prolongation beyond 4
months has previously been suggested by a time-dependent
analysis of individual data of 746 patients from 10 clinical
controlled trials.17 The concept, still propagated by many
physicians, that IFN-a treatment for chronic hepatitis B
becomes ineffective after a certain total dose has been
administered, was not supported by that study. Individual
studies comparing the different lengths of IFN-a therapy in
chronic hepatitis B are scarce. In a study from the United
Kingdom that compared the effectiveness of 12 and 24 weeks
of lymphoblastoid interferon, no additional benefit was
observed with prolonged treatment.18 The lack of favorable
response in patients scheduled for the 24 weeks of therapy
could well have been caused by a poor tolerance of the longer
course. Only 8 of the 20 patients in that study were able to
complete the full 24 weeks of treatment, and none were able
to continue on full dose. In the present study, this problem
was, to a large extent, circumvented by randomizing only
those patients willing to continue therapy after 16 weeks of
treatment.
The pretreatment level of viral replication as indicated by
quantitative HBV-DNA values in serum has been implicated
as a strong response predictive variable in many studies on
IFN-a therapy of chronic hepatitis B.4,19 In the present study,
serum HBV-DNA level after 16 weeks of treatment was the
only significant feature to predict beneficial response as a
result of prolongation of IFN-a therapy. In fact, only patients
with HBV-DNA levels under 10 pg/mL experienced a sus-
tained response after extension of treatment. This HBV-DNA
cut-off value of 10 pg/mL after 16 weeks of treatment should
be an easy indicator for physicians to select patients eligible
for treatment prolongation. We were unable to obtain a
significant independent predictive value from the relative
decrease of serum HBV DNA during the first 16 weeks of
therapy. However, the HBV-DNA assay used in this study,
employing hybridization in solution, generates a detection
limit of 105 to 107 HBV copies per milliliter.20,21 It may well be
that recently developed, more sensitive HBV-DNA assays or
quantitative HBeAg assays could further optimize response
prediction by indicating an approximating response in case of
continuously decreasing serum HBV-DNA or HBeAg values.22
Therefore, close monitoring of the effects of IFN-a on
quantified markers of viral replication appears essential for an
effective therapeutic strategy.
In spite of the relatively high scheduled dose of IFN-a, the
prolonged-treatment course was, in general, well tolerated.
Serious adverse events including hepatic decompensation,
psychosis, and overt depression were rare, and mainly
occurred during the first 16 weeks of therapy. Frequently
reported side-effects of IFN-a, such as fever, myalgia, mood
changes, and fatigue, are often proclaimed to be minor, but
can be invalidating in personal life and lead to temporary
discontinuation of work. Most of these side-effects did not
become more intense during the period of prolonged treat-
ment. On the contrary, many patients reported to become
FIG. 3. HBeAg clearance for patients in the standard- and prolonged-
therapy groups with HBV-DNA levels above or under 10 pg/mL after 16
weeks of therapy.
TABLE 4. Mean Score 6 SEM of Side-Effects (0 5 none, 1 5 mild,
2 5 moderate) in Week 16 (randomization), Week 32 (end of therapy),
and at the End of the Follow-up Period, as Reported by the Patients
Treated With Prolonged IFN-a Treatment (n 5 61)
Randomization End of Therapy End of Follow-up
Fatigue 0.98 6 0.07 0.80 6 0.08 0.19 6 0.06
Anorexia 0.46 6 0.09 0.34 6 0.08 0.03 6 0.03
Myalgia 0.48 6 0.09 0.43 6 0.08 0.02 6 0.02
Arthralgia 0.33 6 0.07 0.30 6 0.06 0.02 6 0.02
Depressive feelings 0.29 6 0.07 0.30 6 0.07 0.07 6 0.03
Concentration disturbances 0.25 6 0.06 0.31 6 0.07 0.03 6 0.02
Headache* 0.54 6 0.08 0.38 6 0.08 0.02 6 0.02
Hair loss* 0.43 6 0.09 0.69 6 0.10 0.02 6 0.02
*Significant difference between week 16 and week 32 (P , .05).
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somehow accustomed to the toxic effects of IFN-a, and
during the phase of prolonged therapy IFN-a had to be
stopped early in only 3 of the 61 patients. The absence of
profound treatment intolerance during the prolonged IFN-a
regimen is probably related to the design of this study in
which only those patients without major side-effects during
the first 16-week course were randomized to further or no
further treatment.
In conclusion, prolongation of IFN-a treatment signifi-
cantly enhances the response rate in chronic hepatitis B
patients with persistent HBeAg, but a low level of viral
replication (HBV DNA , 10 pg/mL) at the end of the
standard 16-week regimen. We propose, in contrast to the
current concept of a fixed treatment course, an IFN-a
regimen in which treatment duration is modified by on-line
measurement of quantified viral markers. Based on the results
of the present study, patients with HBeAg but low HBV-DNA
levels after 16 weeks of IFN-a therapy should be offered
treatment prolongation.
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APPENDIX
The following centers and investigators participated in this
study (values in parenthesis denote the number of patients
recruited): the Netherlands: University Hospital Dijkzigt,
Rotterdam: H. L. A. Janssen, P. Honkoop, H. Snobl, S. W.
Schalm (27); Rijnstate Hospital, Arnhem: R. A. de Vries,
C. J. J. Mulder (9); University Hospital Utrecht, Utrecht: J.
van Hattum, M.C. Rasch (8). Germany: Johannes Gutenberg
Universita¨t, Mainz: G. Gerken, G. Teuber (33); Medizinische
Hochschule Hannover, Hannover: M. P. Manns (1). Belgium:
University Hospital Antwerp, Antwerp: P. Michielsen (5);
Hoˆpital Erasme, Brussels: M. Adler (5); University Hospital
Gasthuisberg, Leuven: F. Nevens, J. Fevery (4); Academic
Hospital Free University, Brussels: M. L. Hautekeetet (3);
Hoˆpitaux St. Joseph, Gilly: R. Brenard (2). United Kingdom:
King’s College, London: N. Naoumov, R. Williams (8).
Denmark: Rigshospitalet, Copenhagen: H. Ring-Larsen (8);
Marselisborg Hospital, Århus: M. R. Buhl (2). France: Hoˆpital
Beaujon, Clichy: P. Marcellin, N. Boyer (12); Hoˆtel Dieu,
Lyon: C. Trepo (2). Spain: Fundacion Jiminez Diaz, Madrid:
V. Carren˜o, J. A. Quiroga, M. Pardo (12). Italy: Ospedale V
Cervello, Palermo: A. Craxi, O. Lo Iacono, P. Almasio (10);
Clinica Medica II Universita, Padova: G. Giustina, G. Fattov-
ich (3). Greece: General Regional Hospital, Thessaloniki:
G. E. Kitis (8).
REFERENCES
1. Niederau C, Heintges T, Lange S, Goldmann G, Niederau C, Mohr L,
Ha¨ussinger D. Long-term follow-up of HBeAg-positive patients treated
with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-
1427.
2. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM,
Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-
interferon therapy. Ann Intern Med 1991;114:629-634.
3. Fattovich G, Giustina G, Realdi G, Schalm SW, Corrocher R., and the
European Concerted Action of Viral Hepatitis (EUROHEP). Long-term
outcome of HBeAg positive patients with compensated cirrhosis treated
with interferon alpha. HEPATOLOGY 1997;26:1338-1342
4. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J,
et al. A randomized controlled trial of interferon alfa-2b alone and after
prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J
Med 1990;323:295-301.
5. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A,
Hallahan C. Randomized controlled trial of recombinant human a-inter-
feron in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-
1325.
6. Berk L, Schalm SW, De Man RA, Heijtink RA, Berthelot P, Brechot C, et
al. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblas-
toid interferon on HBe-seroconversion in chronic hepatitis B. A multi-
centre randomized controlled trial. J Hepatol 1992;14:305-309.
7. Janssen HLA, Berk L, Heijtink RA, Kate ten FJW, Schalm SW. Alpha-
interferon and zidovudine combination therapy for chronic hepatitis
type B. Results of a randomized placebo-controlled trial. HEPATOLOGY
1993;17:383-388.
8. Heathcote J, Schalm SW, Ciancara J, Farrell G, Feinmann V, Shermann
M, Dhillon AP, et al. Lamivudine and Intron A combination treatment in
patients with chronic hepatitis B infection. J Hepatol 1998;28:S1-S43.
9. Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias JM,
Bassendine M, et al. Prednisolone withdrawal therapy enhances the
effect of human lymphoblastoid interferon in chronic hepatitis B. J
Hepatol 1996;25:803-813.
10. Rakela J, Wood JR, Czaja AJ, O’Brien PC, Taswell HF, Bowyer BA, Lange
SM, et al. Long-term versus short-term treatment with recombinant
interferon alfa-2a in patients with chronic hepatitis B: a prospective
randomized treatment trial. Mayo Clin Proc 1990;65:1330-1335.
11. Saracco G, Mazzella G, Rosina F, Cancellieri C, Lattore V, Raise E, et al. A
controlled trial of human lymphoblastoid interferon in chronic hepatitis
B in Italy. HEPATOLOGY 1989;10:336-341.
12. Janssen HLA, Berk L, Schalm SW, Heijtink RA, Hess G, Rossol S, et al.
The antiviral effect of prolonged intermittent lymphoblastoid alpha-
interferon treatment in chronic hepatitis B. Gut 1992;33:1094-1098.
13. Schalm SW. Eurohep. A European community sponsored concerted
action on viral hepatitis: its rationale and execution. J Hepatol 1992;15:
1-3.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classifica-
tion of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY
1994;19:1513-1520.
15. Knodell RG, Ishak KG, Black WC, Chan TS, Craig R, Kaplowitz N,
Kiernan TW, et al. Formulation and application of a numerical scoring
system for assessing histological activity in asymptomatic chronic active
hepatitis. HEPATOLOGY 1981;1:431-435.
16. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis.
N Engl J Med 1997;336:347-356.
17. Krogsgaard K, Christensen E, Bindslev N, Schalm SW, Andersen PK,
Ring-Larsen H and the European Concerted Action on Viral Hepatitis
(Eurohep). Relation between treatment efficacy and cumulative dose of
alpha interferon in chronic hepatitis B. J Hepatol 1996;25:795-802.
18. Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC. Lympho-
blastoid interferon therapy of chronic hepatitis HBV infection. A
comparison of 12 vs. 24 weeks of thrice weekly treatment. J Hepatol
1987;5:51-58.
19. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic
hepatitis B virus infection will respond to a-interferon therapy? A
statistical analysis of predictive factors. HEPATOLOGY 1989;10:761-763.
20. Kuhns MC, McNamara AL, Cabal CM, Decker RH, Thiers V, Brechot C,
Tiollais P. A new assay for quantitative detection of hepatitis B viral DNA
in human serum. In: Zuckerman AJ, ed. Viral Hepatitis and Liver
Disease, New York: Alan Liss Inc., 1988.
21. Zaaijer HL, Borg ter F, Cuypers HT, Hermus MC, Lelie PN. Comparison
of methods for detection of hepatitis B virus DNA. J Clin Microbiol
1994;32:2088-2091.
22. Butterworth L-A, Prior SL, Buda PJ, Faoagali JL, Cooksley G. Compari-
son of four methods for quantitative measurement of hepatitis B viral
DNA. J Hepatol 1996;24:686-691.
HEPATOLOGY Vol. 30, No. 1, 1999 JANSSEN ET AL. 243
